Vasculitis is a heterogeneous disease that has common clinical manifestation such as fibrinoid necrosis and inflammation of the blood vessels. The manifestation differ depending on the size of blood vessel. It is potentially a life threatening disease, however, if diagnosed early with immediate medical intervention the survival rate for one year increases to almost 90%. Large vessel vasculitis majorly consists of giant cell arteritis and Takayasu arteritis that are highly prevalent in Norway and Germany.
Medium vessel vasculitis comprises polyarteritis nodusa which affects in all age group and mostly half of diagnosed cases have been related to HBV infection. Kawasaki disease is mostly seen in children below 4 years of age majorly affecting the coronary artery. Small vessel vasculitis comprises antineutrophil cytoplasmic autoantibodies (ANCA) associated vasculitis, Churg-Strauss syndrome and microscopic polyangitis, they usually occur in the small blood vessels innervating organs such as kidneys and lungs.
Biologics are leading the drug class segment due to better clinical outcomes in patients suffering with ANCA associated vasculitis and promising biological drugs in the pipeline with enhanced drug safety and efficacy. Cyclophosphamide is still the drug of choice for the treatment of vasculitis used in combination with prednisolone globally, highly recommended in patients showing resistance to rituximab treatment.
Large vessel vasculitis dominated the disease type segment in 2017 on account of increasing number of immunocompromised patients suffering with large vessel vasculitis and rising prevalence of CD4 T cell mediated Takayasu vasculitis in the Caucasian population. Small vessel vasculitis is anticipated to showcase impressive growth in the near future due to rising prevalence of ANCA associated small vessel vasculitis in the Mongolian population and rise in the occurrence of leukocytoclastic vasculitis with palpable purpura due to post viral syndromes and drugs.
North America dominated the vasculitis treatment market owing to the rising prevalence of large vessel vasculitis such as giant cell arteritis and Takayasu arteritis, developed healthcare infrastructure and domicile to key players actively engaged in the drug discovery for vasculitis treatment.
Asia Pacific is set to register excellent growth during the forecast period due to increasing number of geriatric population suffering with small vessel vasculitis, proactive government initiatives to expedite the research activities related to vasculitis treatment and increasing disposable income making it affordable for the ailing patient to receive optimum treatment.
Key Market Movements:
- Rising prevalence of blood vessel inflammatory diseases
- Technological advancement in the diagnostic kits resulting in accurate diagnosis of vasculitis due to overlapping disease manifestation with other inflammatory diseases
- Recent FDA approved biologics contributing towards the growth of Vasculitis treatment market
Key Topics Covered:
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Vasculitis Treatment Market Portraiture
2.2. Global Vasculitis Treatment Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Vasculitis Treatment Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global Vasculitis Treatment Market Share, by Geography, 2017 (US$ Mn)
Chapter 3. Vasculitis Treatment: Market Dynamics and Outlook
3.1. Market Overview
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Vasculitis Treatment Market, by Key Players, 2017
Chapter 4. Global Vasculitis Treatment Market, by Drug Class, 2016-2026 (US$ Mn)
4.5. Pipeline Analysis
4.5.1. Tabular Representation of Phase I and Phase II Drugs
Chapter 5. Global Vasculitis Treatment Market, by Disease Condition, 2016-2026 (US$ Mn)
5.2. Large Vessel Vasculitis
5.3. Medium Vessel Vasculitis
5.4. Small Vessel Vasculitis
Chapter 6. Global Vasculitis Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
Chapter 7. Company Profiles
- F.Hoffman La Roche Ltd.
- Baxter International
- Bristol Myers Squibb Company
- Celgene Corporaion
- Daiichi Sankyo
- Eli Lilly & Company
- GlaxoSmithKline Plc
- Merck & Co.
For more information about this report visit https://www.researchandmarkets.com/research/t3g9nz/global_vasculitis?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-vasculitis-treatment-market-2018-2026-market-was-valued-at-us-365-1-mn-in-2017-and-expected-to-reach-us-601-2-mn-by-2026–300665598.html
SOURCE Research and Markets
Read on The Source